SUBSCRIBE
SUBSCRIBE
News   Policy

Hemispherx Biopharma Responding to FDA’s Ampligen Questions

November 3, 2009 | 
1 min read

Bookmark and Share

Philadelphia Business Journal -- Hemispherx Biopharma said Monday its plans to “complete all outstanding queries” from the Food and Drug Administration regarding the company’s new drug application for Ampligen this month and next.

Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
South side and Dome of the US Capitol in Washington DC, United States
Government
RFK Jr. Passes First Hurdle as Nomination Moves to Full Senate Vote
February 4, 2025
 · 
3 min read
 · 
Tristan Manalac
Weigh scales on pink background, top view with space for text. Overweight concept
Obesity
UK Pharmacies Regulator Wants Tighter Checks on Weight Loss Injections
February 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
Trump’s Tariffs Threaten Big Pharma With Higher Costs and Slimmer Margins
February 3, 2025
 · 
3 min read
 · 
Tristan Manalac
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Indivior, SpringWorks, More
February 3, 2025
 · 
5 min read
 · 
Tristan Manalac